Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 5.6%

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shares fell 5.6% on Wednesday . The stock traded as low as $33.72 and last traded at $33.72. 4,994 shares changed hands during trading, a decline of 99% from the average session volume of 482,226 shares. The stock had previously closed at $35.71.

Several brokerages recently weighed in on RXRX. JPMorgan Chase & Co. began coverage on shares of Recursion Pharmaceuticals in a research report on Tuesday, May 11th. They set a “neutral” rating and a $32.00 price target for the company. Bank of America started coverage on shares of Recursion Pharmaceuticals in a research report on Tuesday, May 11th. They set a “buy” rating and a $31.00 price target for the company. The Goldman Sachs Group started coverage on Recursion Pharmaceuticals in a report on Tuesday, May 11th. They issued a “neutral” rating and a $34.00 price objective for the company. SVB Leerink started coverage on Recursion Pharmaceuticals in a report on Tuesday, May 11th. They issued an “outperform” rating and a $33.00 price objective for the company. Finally, KeyCorp began coverage on Recursion Pharmaceuticals in a report on Tuesday, May 11th. They issued an “overweight” rating and a $36.00 price objective for the company. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Recursion Pharmaceuticals has a consensus rating of “Buy” and an average target price of $33.20.

The company’s 50 day moving average price is $28.69.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Wednesday, May 12th. The company reported ($1.33) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($1.09). The business had revenue of $2.56 million during the quarter. As a group, equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.1 earnings per share for the current fiscal year.

Recursion Pharmaceuticals Company Profile (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development.

Read More: Does the Step Transaction Doctrine Affect a Backdoor Roth IRA?

Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.